Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
Status:
Completed
Trial end date:
2019-04-18
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real
world setting in adult patients with advanced or metastatic, epidermal growth factor receptor
(EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior
EGFR-tyrosine kinase inhibitor (TKI) therapy.